Skip to main content

References

📍 Where we are: The full list of sources cited across the book, gathered in one place.

This page is the book's bibliography: every source any chapter cites is listed here. Each inline citation in the book is written as a bracketed marker like [1], and that marker points to a full source listed here, grouped by chapter. The numbering on this page matches the [N] markers in each chapter.

A note on two conventions you will see repeatedly below. For ICH guidelines, "Step 4" means the guideline has reached the final, adopted stage of the ICH harmonisation process — the version regulators expect industry to implement, rather than an earlier draft. For ASTM standards, a designation like E2078-00(2024) combines the original publication year (-00, here 2000) with the year the standard was last reaffirmed ((2024)).

Preface​

  1. Rathore AS, Winkle H. (2009). Quality by design for biopharmaceuticals. Nature Biotechnology 27(1):26-34. https://doi.org/10.1038/nbt0109-26
  2. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA, CDER/CVM/ORA, September 2004. https://www.fda.gov/media/71012/download
  3. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data 3:160018. https://doi.org/10.1038/sdata.2016.18
  4. FDA (U.S. Food and Drug Administration). (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers - Guidance for Industry. FDA, CDER/CBER/CVM, December 2018, Docket FDA-2018-D-3984. https://www.fda.gov/media/119267/download
  5. ISPE (International Society for Pharmaceutical Engineering). (2023). ISPE Baseline Guide Volume 8: Pharma 4.0 (First Edition). ISPE, Baseline Guide Vol. 8, December 2023. https://guidance-docs.ispe.org/doi/book/10.1002/9781946964724
  6. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. Step 4, August 2009. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
  7. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q9(R1): Quality Risk Management. Step 4, January 2023. https://database.ich.org/sites/default/files/ICH_Q9-R1_Guideline_Step4_2023_0126.pdf
  8. ICH (International Council for Harmonisation). (2008). ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System. Step 4, June 2008. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf
  9. ICH (International Council for Harmonisation). (2019). ICH Harmonised Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. Step 4, November 2019. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf
  10. ICH (International Council for Harmonisation). (2022). ICH Harmonised Guideline Q13: Continuous Manufacturing of Drug Substances and Drug Products. Step 4, November 2022. https://database.ich.org/sites/default/files/ICH_Q13_Step4_Guideline_2023_0310.pdf
  11. NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals). U.S. Manufacturing USA institute. https://niimbl.org

Chapter 1 — The Biologic and Its Data Shadow​

  1. Rathore AS, Winkle H. (2009). Quality by design for biopharmaceuticals. Nature Biotechnology 27(1):26-34. https://doi.org/10.1038/nbt0109-26
  2. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. ICH, Current Step 4 version, August 2009. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
  3. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry: PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. FDA, CDER/CVM/ORA, September 2004. https://www.fda.gov/media/71012/download
  4. FDA (U.S. Food and Drug Administration). (2024). 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 211 (Subpart J, Records and Reports). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211
  5. FDA (U.S. Food and Drug Administration). (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers - Guidance for Industry. FDA, CDER/CBER/CVM, December 2018, Docket FDA-2018-D-3984. https://www.fda.gov/media/119267/download
  6. FDA (U.S. Food and Drug Administration). (1997). 21 CFR Part 11 - Electronic Records; Electronic Signatures. U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter A, Part 11 (Final Rule, Federal Register 62(54):13430-13466). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
  7. Banner M, Alosert H, Spencer C, Cheeks M, Farid SS, Thomas M, Goldrick S. (2021). A decade in review: use of data analytics within the biopharmaceutical sector. Current Opinion in Chemical Engineering 34:100758. https://doi.org/10.1016/j.coche.2021.100758
  8. Narayanan H, Luna MF, von Stosch M, Cruz Bournazou MN, Polotti G, Morbidelli M, Butte A, Sokolov M. (2020). Bioprocessing in the Digital Age: The Role of Process Models. Biotechnology Journal 15(1):e1900172. https://doi.org/10.1002/biot.201900172
  9. CMC Biotech Working Group. (2009). A-Mab: A Case Study in Bioprocess Development (Version 2.1). CASSS / ISPE, Emeryville, CA. https://www.casss.org/papers-and-presentations/resource/a-mab-a-case-study-in-bioprocess-development
  10. ISPE (International Society for Pharmaceutical Engineering). (2022). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition). ISPE, Second Edition, July 2022. https://guidance-docs.ispe.org/doi/book/10.1002/9781946964571
  11. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q14: Analytical Procedure Development. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116.pdf
  12. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q2-R2_Guideline_2023_1130.pdf

Chapter 2 — The Lifecycle of a Data Point​

  1. MHRA (Medicines and Healthcare products Regulatory Agency). (2018). 'GXP' Data Integrity Guidance and Definitions, Revision 1. Medicines and Healthcare products Regulatory Agency (UK), March 2018. https://assets.publishing.service.gov.uk/media/5aa2b9ede5274a3e391e37f3/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf
  2. WHO (World Health Organization), Expert Committee on Specifications for Pharmaceutical Preparations. (2021). Guideline on Data Integrity (Annex 4). WHO Technical Report Series No. 1033, 55th report, Annex 4. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/inspections/trs1033-annex4-guideline-on-data-integrity.pdf
  3. PIC/S (Pharmaceutical Inspection Co-operation Scheme). (2021). Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1). Pharmaceutical Inspection Co-operation Scheme, PI 041-1, 1 July 2021, 63 pp. https://picscheme.org/docview/4234
  4. FDA (U.S. Food and Drug Administration). (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers — Guidance for Industry. U.S. FDA / CDER / CBER / CVM, Final guidance, December 2018, Docket FDA-2018-D-3984. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
  5. ISPE (International Society for Pharmaceutical Engineering), GAMP Community of Practice. (2017). ISPE GAMP Guide: Records and Data Integrity. International Society for Pharmaceutical Engineering (ISPE), March 2017. https://ispe.org/publications/guidance-documents/gamp-records-pharmaceutical-data-integrity
  6. McDowall, R. D. (2018). Data Integrity and Data Governance: Practical Implementation in Regulated Laboratories. The Royal Society of Chemistry, 598 pp. (Ch. 9 'An Analytical Data Life Cycle'; Ch. 18 'Record Retention'). https://doi.org/10.1039/9781788013277
  7. DAMA International. (2017). DAMA-DMBOK: Data Management Body of Knowledge, 2nd Edition. Technics Publications, 590 pp., ISBN 978-1-63462-234-9. https://technicspub.com/dmbok2/
  8. Kavasidis, I.; Lallas, E.; Leligkou, H. C.; Oikonomidis, G.; Karydas, D.; Gerogiannis, V. C.; Karageorgos, A. (2023). Deep Transformers for Computing and Predicting ALCOA+ Data Integrity Compliance in the Pharmaceutical Industry. Applied Sciences, 13(13):7616. https://doi.org/10.3390/app13137616
  9. Allotrope Foundation. (2024). Allotrope Data Format (ADF) and Analytical Information Markup Language (AnIML): Allotrope Framework for Standardized Analytical Data. Allotrope Foundation. https://www.allotrope.org/

Chapter 3 — A Tour of Where Process Data Is Born​

  1. Rathore AS, Bhambure R, Ghare V. (2010). Process analytical technology (PAT) for biopharmaceutical products. Analytical and Bioanalytical Chemistry 398(1):137-154. https://doi.org/10.1007/s00216-010-3781-x
  2. Glassey J, Gernaey KV, Clemens C, Schulz TW, Oliveira R, Striedner G, Mandenius C-F. (2011). Process analytical technology (PAT) for biopharmaceuticals. Biotechnology Journal 6(4):369-377. https://doi.org/10.1002/biot.201000356
  3. Konstantinov KB, Cooney CL. (2015). White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268
  4. Abu-Absi NR, Kenty BM, Cuellar ME, Borys MC, Sakhamuri S, Strachan DJ, Hausladen MC, Li ZJ. (2011). Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe. Biotechnology and Bioengineering 108(5):1215-1221. https://doi.org/10.1002/bit.23023
  5. Rathore AS, Parr L, Dermawan S, Lawson K, Lu Y. (2010). Large scale demonstration of a process analytical technology application in bioprocessing: use of on-line high performance liquid chromatography for making real time pooling decisions for process chromatography. Biotechnology Progress 26(2):448-457. https://doi.org/10.1002/btpr.320
  6. Luttmann R, Bracewell DG, Cornelissen G, Gernaey KV, Glassey J, Hass VC, Kaiser C, Preusse C, Striedner G, Mandenius C-F. (2012). Soft sensors in bioprocessing: a status report and recommendations. Biotechnology Journal 7(8):1040-1048. https://doi.org/10.1002/biot.201100506
  7. Lee SL, O'Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, Moore CMV, Yu LX, Woodcock J. (2015). Modernizing pharmaceutical manufacturing: from batch to continuous production. Journal of Pharmaceutical Innovation 10(3):191-199. https://doi.org/10.1007/s12247-015-9215-8
  8. FDA (U.S. Food and Drug Administration, CDER/CVM/ORA). (2004). Guidance for Industry. PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. U.S. Department of Health and Human Services, FDA, Rockville, MD (Sept. 2004). https://www.fda.gov/media/71012/download
  9. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q2-R2_Guideline_2023_1130.pdf
  10. ICH (International Council for Harmonisation). (2022). ICH Harmonised Guideline Q13: Continuous Manufacturing of Drug Substances and Drug Products. Step 4, November 2022. https://database.ich.org/sites/default/files/ICH_Q13_Step4_Guideline_2023_0310.pdf

Chapter 4 — Instruments and Sensors as Data Sources​

  1. US FDA (CDER, CVM, ORA). (2004). Guidance for Industry — PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. U.S. Food and Drug Administration, Rockville, MD (Docket FDA-2003-D-0032). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance
  2. Rathore AS, Bhambure R, Ghare V. (2010). Process analytical technology (PAT) for biopharmaceutical products. Analytical and Bioanalytical Chemistry 398(1):137-154. https://doi.org/10.1007/s00216-010-3781-x
  3. Lourenço ND, Lopes JA, Almeida CF, Sarraguça MC, Pinheiro HM. (2012). Bioreactor monitoring with spectroscopy and chemometrics: a review. Analytical and Bioanalytical Chemistry 404(4):1211-1237. https://doi.org/10.1007/s00216-012-6073-9
  4. Abu-Absi NR, Kenty BM, Cuellar ME, Borys MC, Sakhamuri S, Strachan DJ, Hausladen MC, Li ZJ. (2011). Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe. Biotechnology and Bioengineering 108(5):1215-1221. https://doi.org/10.1002/bit.23023
  5. Esmonde-White KA, Cuellar M, Uerpmann C, Lenain B, Lewis IR. (2017). Raman spectroscopy as a process analytical technology for pharmaceutical manufacturing and bioprocessing. Analytical and Bioanalytical Chemistry 409(3):637-649. https://doi.org/10.1007/s00216-016-9824-1
  6. Esmonde-White KA, Cuellar M, Lewis IR. (2022). The role of Raman spectroscopy in biopharmaceuticals from development to manufacturing. Analytical and Bioanalytical Chemistry 414(2):969-991. https://doi.org/10.1007/s00216-021-03727-4
  7. Claßen J, Aupert F, Reardon KF, Solle D, Scheper T. (2017). Spectroscopic sensors for in-line bioprocess monitoring in research and pharmaceutical industrial application. Analytical and Bioanalytical Chemistry 409(3):651-666. https://doi.org/10.1007/s00216-016-0068-x
  8. ICH. (2023). ICH Q14: Analytical Procedure Development. International Council for Harmonisation, Step 4 (adopted 1 Nov 2023). https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116.pdf
  9. Rogers RS, Nightlinger NS, Livingston B, Campbell P, Bailey R, Balland A. (2015). Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics. mAbs 7(5):881-890. https://doi.org/10.1080/19420862.2015.1069454
  10. FDA (U.S. Food and Drug Administration). (2024). 21 CFR 211.194 - Laboratory records (within 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals). U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 211, Subpart J. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.194
  11. European Commission (EudraLex Volume 4, EU GMP). (2011). EudraLex Volume 4, Good Manufacturing Practice, Annex 11: Computerised Systems (Section 5, Data). European Commission, Health and Consumers Directorate-General; EudraLex Volume 4 GMP Guidelines. https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf
  12. Rathore AS, Singh SK. (2015). Use of Multivariate Data Analysis in Bioprocessing. BioPharm International 28(6):26-31.
  13. FDA (U.S. Food and Drug Administration). (2024). 21 CFR 211.160 and 211.165 — General requirements for laboratory controls and Testing and release for distribution (within 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals). U.S. Code of Federal Regulations, Title 21, Chapter I, Subchapter C, Part 211, Subpart I. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-I
  14. ISPE (International Society for Pharmaceutical Engineering). (2022). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition). ISPE, July 2022 (Appendix D11 addresses AI/ML).
  15. European Commission / EMA. (2025). EudraLex Volume 4, EU GMP Annex 11: Computerised Systems — Revised Draft for Public Consultation. Published 7 July 2025 (consultation closed October 2025; finalization expected 2026); expands coverage to audit-trail review, cloud/SaaS service providers, data integrity across networked multi-system environments and AI/ML, and formalizes ALCOA+. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

Chapter 5 — Automation and Process Control Data​

  1. International Society of Automation (ISA); ANSI. (2010). ANSI/ISA-88.00.01-2010, Batch Control Part 1: Models and Terminology. International Society of Automation (ISA), Research Triangle Park, NC. https://www.isa.org/products/isa-88-00-01-2010-batch-control-part-1-models
  2. International Society of Automation (ISA); ANSI. (2025). ANSI/ISA-95.00.01-2025 (IEC 62264-1 Mod), Enterprise-Control System Integration Part 1: Models and Terminology. International Society of Automation (ISA), Research Triangle Park, NC. https://www.isa.org/products/ansi-isa-95-00-01-2025-iec-62264-1-mod-enterprise
  3. International Electrotechnical Commission (IEC); ISO. (2013). IEC 62264-1:2013, Enterprise-control system integration - Part 1: Models and terminology (Edition 2.0). International Electrotechnical Commission (IEC), Geneva, jointly with ISO TC184/SC5. https://www.iso.org/standard/57308.html
  4. NAMUR (User Association of Automation Technology in Process Industries). (2003). NAMUR NE 33: Requirements to be met by Systems for Recipe-Based Operations. NAMUR, Leverkusen, Germany (Recommendation NE 033, dated 2003-01-17). https://www.namur.net/en/work-areas-and-project-groups/wa-2-automation-systems-for-processes-and-plants/wg-23-batch-control.html
  5. International Society of Automation (ISA); ANSI. (2016). ANSI/ISA-18.2-2016, Management of Alarm Systems for the Process Industries. International Society of Automation (ISA), Research Triangle Park, NC. https://www.isa.org/products/ansi-isa-18-2-2016-management-of-alarm-systems-for
  6. International Electrotechnical Commission (IEC). (2025). IEC 61131-3:2025, Programmable controllers - Part 3: Programming languages (Edition 4.0). International Electrotechnical Commission (IEC), Geneva (TC65/SC65B). https://webstore.iec.ch/en/publication/68533
  7. Godena G., Lukman T., Steiner I., Bergant F., Strmcnik S. (2015). A new object model of batch equipment and procedural control for better recipe reuse. Computers in Industry, 70:46-55. https://doi.org/10.1016/j.compind.2015.02.002
  8. U.S. Food and Drug Administration (FDA). (2003). Guidance for Industry - Part 11, Electronic Records; Electronic Signatures - Scope and Application. U.S. FDA, Center for Drug Evaluation and Research (Docket FDA-2003-D-0143). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application
  9. U.S. Food and Drug Administration (FDA). (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers - Guidance for Industry. U.S. FDA, CDER/CBER/CVM (finalized December 2018; Docket FDA-2018-D-3984). https://www.fda.gov/media/119267/download
  10. European Commission (EudraLex Volume 4, EU GMP). (2011). EudraLex Volume 4, Good Manufacturing Practice, Annex 11: Computerised Systems. European Commission, Health and Consumers Directorate-General; EudraLex Volume 4 GMP Guidelines. https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf
  11. Pharmaceutical Inspection Co-operation Scheme (PIC/S). (2021). Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1). Pharmaceutical Inspection Co-operation Scheme, PI 041-1, entered into force 1 July 2021, 63 pp. https://picscheme.org/docview/4234
  12. U.S. Food and Drug Administration (FDA). (2004). Guidance for Industry - PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. U.S. FDA, CDER/CVM/ORA, September 2004. https://www.fda.gov/media/71012/download
  13. ICH (International Council for Harmonisation). (2009). ICH Harmonised Tripartite Guideline Q8(R2): Pharmaceutical Development. Step 4, August 2009. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf
  14. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q9(R1): Quality Risk Management. Step 4, January 2023. https://database.ich.org/sites/default/files/ICH_Q9-R1_Guideline_Step4_2023_0126.pdf
  15. ICH (International Council for Harmonisation). (2008). ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System. Step 4, June 2008. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf
  16. ICH (International Council for Harmonisation). (2022). ICH Harmonised Guideline Q13: Continuous Manufacturing of Drug Substances and Drug Products. Step 4, November 2022. https://database.ich.org/sites/default/files/ICH_Q13_Step4_Guideline_2023_0310.pdf

Chapter 6 — The Plant Information Systems: Historian, MES, LIMS, and ELN​

  1. International Society of Automation (ISA). (2025). ANSI/ISA-95.00.01-2025 (IEC 62264-1 Mod), Enterprise-Control System Integration - Part 1: Models and Terminology. International Society of Automation (ISA); modified adoption of IEC 62264-1. https://www.isa.org/products/ansi-isa-95-00-01-2025-iec-62264-1-mod-enterprise
  2. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3:160018. https://doi.org/10.1038/sdata.2016.18
  3. International Society for Pharmaceutical Engineering (ISPE). (2023). ISPE Baseline Guide Volume 8: Pharma 4.0 (First Edition). International Society for Pharmaceutical Engineering (ISPE); Baseline Guide Vol. 8, December 2023. https://guidance-docs.ispe.org/doi/book/10.1002/9781946964724
  4. US Food and Drug Administration (FDA). (1997). 21 CFR Part 11 - Electronic Records; Electronic Signatures (Final Rule). US Code of Federal Regulations, Title 21, Part 11; Final Rule 62 FR 13430, 20 March 1997. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
  5. US Food and Drug Administration (FDA). (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers - Guidance for Industry. US FDA, CDER/CBER/CVM; Docket FDA-2018-D-3984 (Final, December 2018). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
  6. International Society for Pharmaceutical Engineering (ISPE). (2022). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition). International Society for Pharmaceutical Engineering (ISPE); GAMP 5 Guide, 2nd Edition, July 2022. https://guidance-docs.ispe.org/doi/book/10.1002/9781946964571
  7. International Electrotechnical Commission (IEC). (2020). IEC TR 62541-1:2020, OPC Unified Architecture - Part 1: Overview and concepts. International Electrotechnical Commission, Geneva; IEC 62541 series (OPC UA), Part 1 of the multi-part standard. https://webstore.iec.ch/publication/61109
  8. Pharmaceutical Inspection Co-operation Scheme (PIC/S). (2021). Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1). Pharmaceutical Inspection Co-operation Scheme (PIC/S), Geneva; PI 041-1, in force 1 July 2021. https://picscheme.org/docview/4234
  9. Chen Y, Yang O, Sampat C, Bhalode P, Ramachandran R, Ierapetritou M. (2020). Digital Twins in Pharmaceutical and Biopharmaceutical Manufacturing: A Literature Review. Processes, 8(9):1088. https://doi.org/10.3390/pr8091088
  10. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q14: Analytical Procedure Development. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116.pdf
  11. European Commission / EMA. (2025). EudraLex Volume 4, EU GMP Annex 11: Computerised Systems — Revised Draft for Public Consultation. Published 7 July 2025 (consultation closed October 2025; finalization expected 2026); expands coverage to audit-trail review, cloud/SaaS service providers, data integrity across networked multi-system environments and AI/ML, and formalizes ALCOA+. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  12. US Food and Drug Administration (FDA). 21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals. US Code of Federal Regulations, Title 21, Part 211 (master production and control records §211.186; batch production and control records §211.188). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211
  13. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q2-R2_Guideline_2023_1130.pdf

Chapter 7 — Architecture and Integration: ISA-95, OT/IT, and the Edge-to-Cloud Path​

  1. Williams TJ. (1994). The Purdue Enterprise Reference Architecture. Computers in Industry 24(2-3):141-158. https://doi.org/10.1016/0166-3615(94)90017-5
  2. International Society of Automation (ISA). (2025). ANSI/ISA-95.00.01-2025 (IEC 62264-1 Mod), Enterprise-Control System Integration - Part 1: Models and Terminology. International Society of Automation, Research Triangle Park, NC; standard ANSI/ISA-95.00.01-2025. https://www.isa.org/products/ansi-isa-95-00-01-2025-iec-62264-1-mod-enterprise
  3. Stouffer K, Pease M, Tang C, Zimmerman T, Pillitteri V, Lightman S, Hahn A, Saravia S, Sherule A, Thompson M. (2023). Guide to Operational Technology (OT) Security. NIST Special Publication 800-82 Revision 3, National Institute of Standards and Technology. https://doi.org/10.6028/NIST.SP.800-82r3
  4. International Electrotechnical Commission (IEC) / ISA99 committee. (2013). IEC 62443-3-3: Industrial communication networks - Network and system security - Part 3-3: System security requirements and security levels. International Electrotechnical Commission, Geneva; standard IEC 62443-3-3:2013. https://webstore.iec.ch/publication/7033
  5. Venanzi R, Di Modica G, Foschini L, Bellavista P. (2025). Towards IT/OT integration in industry digitalization: A comprehensive survey. Journal of Network and Computer Applications 245:104373. https://doi.org/10.1016/j.jnca.2025.104373
  6. Eclipse Sparkplug Working Group, Eclipse Foundation. (2022). Sparkplug Specification Version 3.0.0 (MQTT Topic Namespace and Payload Definition for Industrial IoT). Eclipse Foundation Specification Process, ratified 21 Oct 2022. https://sparkplug.eclipse.org/specification/version/3.0/
  7. International Electrotechnical Commission (IEC) / ANSI-ISA. (1997). IEC 61512-1 (ANSI/ISA-88.01): Batch control - Part 1: Models and terminology. International Electrotechnical Commission, Geneva; standard IEC 61512-1:1997. https://webstore.iec.ch/publication/5528
  8. European Commission (EudraLex Volume 4, EU GMP). (2011). EudraLex Volume 4, Good Manufacturing Practice, Annex 11: Computerised Systems. European Commission, Health and Consumers Directorate-General; EudraLex Volume 4 GMP Guidelines. https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf
  9. European Commission / EMA. (2025). EudraLex Volume 4, EU GMP Annex 11: Computerised Systems — Revised Draft for Public Consultation. Published 7 July 2025 (consultation closed October 2025; finalization expected 2026); expands coverage to audit-trail review, cloud/SaaS service providers, data integrity across networked multi-system environments and AI/ML, and formalizes ALCOA+. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  10. U.S. Food and Drug Administration (FDA). (1997). 21 CFR Part 11 - Electronic Records; Electronic Signatures (Final Rule). Federal Register 62 FR 13430 (20 Mar 1997), Docket No. 92N-0251; effective 20 Aug 1997. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11

Chapter 8 — Connectivity and Interoperability Standards​

  1. IEC (International Electrotechnical Commission). (2025). IEC 62541-1:2025 OPC Unified Architecture - Part 1: Overview and concepts. International Electrotechnical Commission, Geneva; IEC 62541-1:2025 (International Standard, Ed. 1.0, supersedes IEC TR 62541-1:2020). https://webstore.iec.ch/en/publication/81513
  2. VDI/VDE/NAMUR (Verein Deutscher Ingenieure / VDE / NAMUR). (2019). VDI/VDE/NAMUR 2658 Part 1: Automation engineering of modular systems in the process industry - General concept and interfaces. VDI-Gesellschaft Mess- und Automatisierungstechnik, Beuth/DIN Media, Berlin; VDI/VDE/NAMUR 2658 Blatt 1:2019-10. https://www.vdi.de/en/home/vdi-standards/details/vdivdenamur-2658-blatt-1-automation-engineering-of-modular-systems-in-the-process-industry-general-concept-and-interfaces
  3. Juchli, D. (2022). SiLA 2: The Next Generation Lab Automation Standard. In: Beutel S., Lenk F. (eds), Smart Biolabs of the Future, Advances in Biochemical Engineering/Biotechnology, vol 182, pp. 147-174, Springer, Cham. https://doi.org/10.1007/10_2022_204
  4. Kayser, H.; Lau, M.-L. (2024). Growing value of data standardization: Allotrope Foundation Connect Workshop Proceedings. Drug Discovery Today, 29(6):103988. https://doi.org/10.1016/j.drudis.2024.103988
  5. Schäfer, B. A.; Poetz, D.; Kramer, G. W. (2004). Documenting Laboratory Workflows Using the Analytical Information Markup Language. Journal of the Association for Laboratory Automation (JALA), 9(6):375-381. https://doi.org/10.1016/j.jala.2004.10.003
  6. ASTM International. (2024). ASTM E2078-00(2024) Standard Guide for Analytical Data Interchange Protocol for Mass Spectrometric Data (with ASTM E2077-00(2024) Standard Specification). ASTM International, West Conshohocken, PA; E2078-00(2024) and E2077-00(2024). https://www.astm.org/e2078-00r24.html
  7. ISA (International Society of Automation) / IEC. (2025). ANSI/ISA-95.00.01-2025 (IEC 62264-1 Mod) Enterprise-Control System Integration - Part 1: Models and Terminology. International Society of Automation, Research Triangle Park, NC; ANSI/ISA-95.00.01-2025 / IEC 62264-1 Mod. https://www.isa.org/products/ansi-isa-95-00-01-2025-iec-62264-1-mod-enterprise
  8. Celebi, I.; Dragoset, R. A.; Olsen, K. J.; Schaefer, R.; Kramer, G. W. (2010). Improving Interoperability by Incorporating UnitsML Into Markup Languages. Journal of Research of the National Institute of Standards and Technology, 115(1):15-22. https://doi.org/10.6028/jres.115.003
  9. Freitas, L.; Pereira, F.; Lopes, H.; Lima, A.; Marujo, P.; Ottaviano, E.; Machado, J. (2024). OPC-UA in interoperability - a performance comparative testing. IFAC-PapersOnLine, 58(8):240-245. https://doi.org/10.1016/j.ifacol.2024.08.127
  10. OPC Foundation. (2026). OPC UA Companion Specifications (technology overview). OPC Foundation, Unified Architecture technology pages; a companion specification is an equipment-domain plug-in that standardizes how a given type of machine exposes its data over OPC UA — the published rulebook (often labelled OPC 10000-NNN, the OPC numbering of the IEC 62541 base) that fixes the names, structure, and units a device of that kind must use. More than 430 were published as of 2026, with none yet for a mammalian-cell bioreactor (CHO = Chinese Hamster Ovary cells, the standard cell line for making antibodies), so that equipment type still has no agreed common data model. https://opcfoundation.org/about/opc-technologies/opc-ua/ua-companion-specifications/
  11. Dahlmanns, M.; Lohmoller, J.; Fink, I. B.; Pennekamp, J.; Wehrle, K.; Henze, M. (2020). Easing the Conscience with OPC UA: An Internet-Wide Study on Insecure Deployments. Proceedings of the ACM Internet Measurement Conference (IMC '20), pp. 101-110. https://doi.org/10.1145/3419394.3423666
  12. OASIS (Organization for the Advancement of Structured Information Standards). (2019). MQTT Version 5.0 — OASIS Standard. OASIS, 7 March 2019. MQTT (Message Queuing Telemetry Transport) is a lightweight publish/subscribe messaging protocol; the earlier MQTT v3.1.1 (OASIS, 2014) was published as the international standard ISO/IEC 20922:2016, Information technology — Message Queuing Telemetry Transport (MQTT) v3.1.1. https://docs.oasis-open.org/mqtt/mqtt/v5.0/mqtt-v5.0.html
  13. Eclipse Foundation (Sparkplug Working Group). (2022). Sparkplug Specification, Version 3.0.0. Eclipse Foundation; an open convention layered on MQTT that makes it usable for industrial plant data — it standardizes how messages are named and organized, lets a system know when a device comes online or drops offline, and sends a value only when it changes rather than on a fixed schedule. https://sparkplug.eclipse.org/specification/version/3.0/documents/sparkplug-specification-3.0.0.pdf

Chapter 9 — Data Integrity and ALCOA+​

  1. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers — Guidance for Industry. FDA, CDER (Final Guidance, December 2018), Docket FDA-2018-D-3984. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
  2. Medicines and Healthcare products Regulatory Agency (MHRA). (2018). 'GXP' Data Integrity Guidance and Definitions, Revision 1. MHRA, UK (March 2018), 21 pp. https://assets.publishing.service.gov.uk/media/5aa2b9ede5274a3e391e37f3/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf
  3. Pharmaceutical Inspection Co-operation Scheme (PIC/S). (2021). Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1). PIC/S, Geneva, PI 041-1, 1 July 2021, 63 pp. https://picscheme.org/docview/4234
  4. World Health Organization (WHO). (2021). Guideline on Data Integrity (Annex 4, WHO Technical Report Series No. 1033). WHO Expert Committee on Specifications for Pharmaceutical Preparations, 55th report, TRS 1033, Annex 4. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/inspections/trs1033-annex4-guideline-on-data-integrity.pdf
  5. European Medicines Agency (EMA), GMP/GDP Inspectors Working Group. (2016). Questions and Answers: Good Manufacturing Practice — Data Integrity. EMA GMP/GDP Compliance Q&As (23 questions on data integrity and the data life cycle). https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/guidance-good-manufacturing-practice-good-distribution-practice-questions-answers
  6. International Society for Pharmaceutical Engineering (ISPE), GAMP Community of Practice. (2017). ISPE GAMP Guide: Records and Data Integrity. ISPE (March 2017), 152 pp. https://guidance-docs.ispe.org/doi/book/10.1002/9781936379965
  7. McDowall RD. (2018). Data Integrity and Data Governance: Practical Implementation in Regulated Laboratories. Royal Society of Chemistry, Cambridge; ISBN 978-1-78801-281-2. https://doi.org/10.1039/9781788013277
  8. Woollen SW. (2010). Data Quality and the Origin of ALCOA. The Compass, Summer 2010, Newsletter of the Southern Regional Chapter, Society of Quality Assurance. https://rx-360.org/wp-content/uploads/2018/08/Data-Quality-and-the-Origin-of-ALCOA-by-Stan-Woolen-2010.pdf
  9. European Medicines Agency (EMA), GMP/GDP Inspectors Working Group. (2022). Concept Paper on the Revision of Annex 11 of the Guidelines on Good Manufacturing Practice for Medicinal Products — Computerised Systems (EMA/INS/GMP/745438/2022). EMA, Amsterdam (16 November 2022); revision extends audit-trail and data-integrity expectations to networked and multi-system environments. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-revision-annex-11-guidelines-good-manufacturing-practice-medicinal-products-computerised-systems_en.pdf
  10. European Commission / EMA. (2025). EudraLex Volume 4, EU GMP Annex 11: Computerised Systems — Revised Draft for Public Consultation. Published 7 July 2025 (consultation closed October 2025; finalization expected 2026); expands coverage to audit-trail review, cloud/SaaS service providers, data integrity across networked multi-system environments and AI/ML, and formalizes ALCOA+. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

Chapter 10 — Records, Signatures, and the Law: 21 CFR Part 11 and EU Annex 11​

  1. FDA (US Food and Drug Administration). (1997). Electronic Records; Electronic Signatures; Final Rule (21 CFR Part 11). Federal Register, 62(54):13430-13466; Docket No. 92N-0251; FR Doc. 97-6833. https://www.federalregister.gov/documents/1997/03/20/97-6833/electronic-records-electronic-signatures
  2. FDA (CDER, CBER, CDRH, CFSAN, CVM, ORA). (2003). Guidance for Industry — Part 11, Electronic Records; Electronic Signatures — Scope and Application. U.S. Food and Drug Administration; Docket No. FDA-2003-D-0143 (announced Federal Register 68 FR, 05 Sep 2003, FR Doc. 03-22574). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application
  3. European Commission (EudraLex Volume 4 GMP). (2011). EudraLex — The Rules Governing Medicinal Products in the European Union, Volume 4, Good Manufacturing Practice, Annex 11: Computerised Systems. European Commission, Health and Consumers Directorate-General; effective 30 June 2011. https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf
  4. ISPE (International Society for Pharmaceutical Engineering). (2022). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition). ISPE, North Bethesda, MD (Second Edition). https://guidance-docs.ispe.org/doi/book/10.1002/9781946964571
  5. MHRA (Medicines and Healthcare products Regulatory Agency). (2018). 'GXP' Data Integrity Guidance and Definitions, Revision 1. UK Medicines and Healthcare products Regulatory Agency, March 2018. https://assets.publishing.service.gov.uk/media/5aa2b9ede5274a3e391e37f3/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf
  6. PIC/S (Pharmaceutical Inspection Co-operation Scheme). (2021). Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1). Pharmaceutical Inspection Co-operation Scheme, PI 041-1, entered into force 1 July 2021. https://picscheme.org/docview/4234
  7. FDA (CDER, CBER, CVM). (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers — Guidance for Industry. U.S. Food and Drug Administration; Docket No. FDA-2018-D-3984 (Federal Register 13 Dec 2018, FR Doc. 2018-26957). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
  8. WHO Expert Committee on Specifications for Pharmaceutical Preparations. (2016). Guidance on Good Data and Record Management Practices (Annex 5, WHO Technical Report Series No. 996). World Health Organization, WHO Technical Report Series No. 996, Annex 5, 2016. https://www.who.int/publications/i/item/WHO_TRS_996
  9. Bansal A, Chamberlain R, Karr S, Kwasa S, McLaughlin B, Nguyen B, Rendell M, Schmit K, Smith C. (2012). A 21 CFR Part 11 Compliant Graphically Based Electronic System for Clinical Research Documentation. Journal of Medical Systems, 36(3):1661-1672. https://doi.org/10.1007/s10916-010-9627-4
  10. EMA (European Medicines Agency). (2022). Concept Paper on the Revision of Annex 11 of the Guidelines on Good Manufacturing Practice for Medicinal Products — Computerised Systems (EMA/INS/GMP/745438/2022). European Medicines Agency, GMP/GDP Inspectors Working Group, 16 November 2022. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/concept-paper-revision-annex-11-guidelines-good-manufacturing-practice-medicinal-products-computerised-systems_en.pdf
  11. European Commission / EMA. (2025). EudraLex Volume 4, EU GMP Annex 11: Computerised Systems — Revised Draft for Public Consultation. Published 7 July 2025 (consultation closed October 2025; finalization expected 2026); expands coverage to audit-trail review, cloud/SaaS service providers, data integrity across networked multi-system environments and AI/ML, and formalizes ALCOA+. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en

Chapter 11 — Validating Computerized Systems: GAMP 5 and the Move to CSA​

  1. ISPE (International Society for Pharmaceutical Engineering). (2022). ISPE GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition). ISPE, Tampa, FL. https://guidance-docs.ispe.org/doi/book/10.1002/9781946964571
  2. U.S. Food and Drug Administration (CDRH, CBER). (2025). Computer Software Assurance for Production and Quality System Software: Guidance for Industry and Food and Drug Administration Staff. U.S. FDA; Federal Register notice 90 FR (24 Sep 2025), Docket FDA-2022-D-0795; finalizes the 13 Sep 2022 draft. https://www.federalregister.gov/documents/2025/09/24/2025-18468/computer-software-assurance-for-production-and-quality-system-software-guidance-for-industry-and
  3. U.S. Food and Drug Administration (CDRH, CBER). (2022). Computer Software Assurance for Production and Quality System Software; Draft Guidance for Industry and Food and Drug Administration Staff; Availability. Federal Register 87 FR 56043 (13 Sep 2022), Docket FDA-2022-D-0795. https://www.federalregister.gov/documents/2022/09/13/2022-19763/computer-software-assurance-for-production-and-quality-system-software-draft-guidance-for-industry
  4. ASTM International (Committee E55). (2025). ASTM E2500-25 Standard Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and Equipment Science and Risk Based Approach. ASTM International, West Conshohocken, PA; revision supersedes E2500-20. https://store.astm.org/e2500-25.html
  5. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q9(R1): Quality Risk Management. ICH; Step 4 adopted 18 Jan 2023 (Step 4 document dated 2022-12-19). https://database.ich.org/sites/default/files/ICH_Q9(R1)_Guideline_Step4_2022_1219.pdf
  6. U.S. Food and Drug Administration (CDRH, CBER). (2002). General Principles of Software Validation; Final Guidance for Industry and FDA Staff. U.S. FDA, issued 11 Jan 2002, Docket No. 97D-0282. https://www.federalregister.gov/documents/2002/01/11/02-690/medical-devices-general-principles-of-software-validation-final-guidance-for-industry-and-fda-staff
  7. European Commission (EudraLex Volume 4, EU GMP). (2011). EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 11: Computerised Systems. European Commission, EudraLex Vol. 4; effective 30 Jun 2011. https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf
  8. U.S. Food and Drug Administration. (1997). 21 CFR Part 11 - Electronic Records; Electronic Signatures (Final Rule). Federal Register 62 FR 13430 (20 Mar 1997), Docket No. 92N-0251; effective 20 Aug 1997. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
  9. Walia, G.; Neri, D. (2024). Computer Software Assurance and the Critical Thinking Approach. Pharmaceutical Engineering (ISPE), March/April 2024. https://ispe.org/pharmaceutical-engineering/march-april-2024/computer-software-assurance-and-critical-thinking
  10. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q14: Analytical Procedure Development. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116.pdf
  11. European Commission / EMA. (2025). EudraLex Volume 4, EU GMP Annex 11: Computerised Systems — Revised Draft for Public Consultation. Published 7 July 2025 (consultation closed October 2025; finalization expected 2026); expands coverage to audit-trail review, cloud/SaaS service providers, data integrity across networked multi-system environments and AI/ML, and formalizes ALCOA+. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  12. U.S. Food and Drug Administration. 21 CFR 211.68 — Automatic, mechanical, and electronic equipment (Current Good Manufacturing Practice for Finished Pharmaceuticals). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-D/section-211.68
  13. FDA (U.S. Food and Drug Administration). (2025). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products — Draft Guidance for Industry. FDA, CDER/CBER, January 2025. https://www.fda.gov/media/184830/download
  14. ISPE (International Society for Pharmaceutical Engineering). (2025). GAMP Guide: Artificial Intelligence. ISPE, 2025.

Chapter 12 — Data Governance, Data Quality, and Master Data​

  1. DAMA International. (2017). DAMA-DMBOK: Data Management Body of Knowledge (2nd Edition). Technics Publications, Denville, NJ; ISBN 978-1-634622-34-9. https://technicspub.com/dmbok2/
  2. Wang RY, Strong DM. (1996). Beyond Accuracy: What Data Quality Means to Data Consumers. Journal of Management Information Systems 12(4):5-33. https://doi.org/10.1080/07421222.1996.11518099
  3. Khatri V, Brown CV. (2010). Designing Data Governance. Communications of the ACM 53(1):148-152. https://doi.org/10.1145/1629175.1629210
  4. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data 3:160018. https://doi.org/10.1038/sdata.2016.18
  5. ISPE (International Society for Pharmaceutical Engineering). (2017). ISPE GAMP Guide: Records and Data Integrity. ISPE, Tampa, FL; ISBN 978-1-936379-96-5. https://guidance-docs.ispe.org/doi/book/10.1002/9781936379965
  6. U.S. Food and Drug Administration. (2018). Data Integrity and Compliance With Drug CGMP: Questions and Answers — Guidance for Industry. FDA, CDER/CBER/CVM; Docket FDA-2018-D-3984. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
  7. Medicines and Healthcare products Regulatory Agency (MHRA). (2018). 'GXP' Data Integrity Guidance and Definitions, Revision 1. MHRA, UK Government (gov.uk). https://assets.publishing.service.gov.uk/media/5aa2b9ede5274a3e391e37f3/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf
  8. World Health Organization (WHO). (2021). Guideline on data integrity (WHO Technical Report Series No. 1033, Annex 4). WHO Expert Committee on Specifications for Pharmaceutical Preparations, 55th report; WHO, Geneva. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/inspections/trs1033-annex4-guideline-on-data-integrity.pdf
  9. International Organization for Standardization (ISO). (2022). ISO 8000-1:2022 Data quality — Part 1: Overview. ISO, Geneva (ISO/TC 184/SC 4); supersedes ISO/TS 8000-1:2011. https://www.iso.org/standard/81745.html
  10. International Organization for Standardization (ISO). (2021). ISO 8000-110:2021 Data quality — Part 110: Master data: Exchange of characteristic data: Syntax, semantic encoding, and conformance to data specification. ISO, Geneva (ISO/TC 184/SC 4). https://www.iso.org/standard/81233.html
  11. U.S. Food and Drug Administration. (current). 21 CFR 211.184 & 211.188 — Component, drug product container, closure, and labeling records; Batch production and control records (Current Good Manufacturing Practice for Finished Pharmaceuticals). FDA, Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J
  12. GS1. GS1 General Specifications (GTIN/GLN/SSCC identifiers). https://www.gs1.org
  13. U.S. FDA. Drug Supply Chain Security Act (DSCSA). https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa

Chapter 13 — Why Numbers Don't Connect: The Semantic Interoperability Problem​

  1. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data 3:160018. https://doi.org/10.1038/sdata.2016.18
  2. International Electrotechnical Commission (IEC); International Organization for Standardization (ISO) [based on ANSI/ISA-95.00.01-2010]. (2013). IEC 62264-1:2013 Enterprise-control system integration — Part 1: Models and terminology (2nd ed.). IEC/ISO, Geneva (double-logo standard; IEC TC 65/SC 65E with ISO TC 184/SC 5). https://www.iso.org/standard/57308.html
  3. Karray MH, Otte N, Rai R, Ameri F, Kulvatunyou B, Smith B, Kiritsis D, Will C, Arista R. (2021). The Industrial Ontologies Foundry (IOF) perspectives. Proc. I-ESA 2020 IOF 'Achieving Data Interoperability' Workshop, Tarbes, France (NIST pub. 925879). https://www.nist.gov/publications/industrial-ontologies-foundry-iof-perspectives
  4. Drobnjakovic M, Kulvatunyou B, Ameri F, Will C, Smith B, Jones AT. (2022). The Industrial Ontologies Foundry (IOF) Core Ontology. CEUR Workshop Proceedings, vol. 3240 (FOMI 2022, 12th Int. Workshop on Formal Ontologies meet Industry), Tarbes, France. https://ceur-ws.org/Vol-3240/paper3.pdf
  5. Uschold M, Gruninger M. (1996). Ontologies: principles, methods and applications. The Knowledge Engineering Review 11(2):93–136. https://doi.org/10.1017/S0269888900007797
  6. Tolk A, Muguira JA. (2003). The Levels of Conceptual Interoperability Model (LCIM). Proc. 2003 Fall Simulation Interoperability Workshop, Orlando, FL (paper 03F-SIW-007), Simulation Interoperability Standards Organization (SISO), pp. 1–11. https://www.mscoe.org/content/uploads/2017/12/Tolk-Muguira-The-Levels-of-Conceptual-Interoperability-Models.pdf
  7. International Organization for Standardization / International Electrotechnical Commission (ISO/IEC). (2021). ISO/IEC 21838-2:2021 Information technology — Top-level ontologies (TLO) — Part 2: Basic Formal Ontology (BFO). ISO/IEC, Geneva (ISO/IEC JTC 1). https://www.iso.org/standard/74572.html
  8. Kayser H, Lau M-L. (2024). Growing value of data standardization: Allotrope Foundation Connect Workshop Proceedings. Drug Discovery Today 29(6):103988. https://doi.org/10.1016/j.drudis.2024.103988
  9. International Society for Pharmaceutical Engineering (ISPE). (2022). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition) — including ALCOA+ data-integrity principles and the data life cycle. ISPE, North Bethesda, MD. https://ispe.org/publications/guidance-documents/gamp-5-guide-2nd-edition
  10. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2023). ICH Q2(R2) Validation of Analytical Procedures. ICH, Geneva. https://www.ich.org/page/quality-guidelines
  11. ICH. (2023). ICH Q14: Analytical Procedure Development. International Council for Harmonisation, Step 4 (adopted 1 Nov 2023). https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116.pdf

Chapter 14 — Ontologies and FAIR Data​

  1. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data 3:160018. https://doi.org/10.1038/sdata.2016.18
  2. Smith B, Ashburner M, Rosse C, et al. (OBI Consortium). (2007). The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nature Biotechnology 25(11):1251-1255. https://doi.org/10.1038/nbt1346
  3. Arp R, Smith B, Spear AD. (2015). Building Ontologies with Basic Formal Ontology. MIT Press, Cambridge, MA (ISBN 9780262527811). https://doi.org/10.7551/mitpress/9780262527811.001.0001
  4. ISO/IEC (Joint Technical Committee JTC 1). (2021). Information technology - Top-level ontologies (TLO) - Part 2: Basic Formal Ontology (BFO). ISO/IEC 21838-2:2021, International Organization for Standardization. https://www.iso.org/standard/74572.html
  5. Drobnjakovic M, Kulvatunyou B, Ameri F, Will C, Smith B, Jones A. (2022). The Industrial Ontologies Foundry (IOF) Core Ontology. Formal Ontologies Meet Industry (FOMI) 2022, CEUR Workshop Proceedings Vol-3240, paper 3. https://ceur-ws.org/Vol-3240/paper3.pdf
  6. Kulvatunyou B, Wallace E, Kiritsis D, Smith B, Will C. (2018). The Industrial Ontologies Foundry Proof-of-Concept Project. Advances in Production Management Systems (APMS 2018), IFIP AICT vol 536, Springer, pp 402-409. https://doi.org/10.1007/978-3-319-99707-0_50
  7. Cyganiak R, Wood D, Lanthaler M (eds.). (2014). RDF 1.1 Concepts and Abstract Syntax. W3C Recommendation, 25 February 2014, World Wide Web Consortium. https://www.w3.org/TR/2014/REC-rdf11-concepts-20140225/
  8. W3C OWL Working Group; Hitzler P, Krötzsch M, Parsia B, Patel-Schneider PF, Rudolph S (eds.). (2012). OWL 2 Web Ontology Language Document Overview (Second Edition). W3C Recommendation, 11 December 2012, World Wide Web Consortium. https://www.w3.org/TR/2012/REC-owl2-overview-20121211/
  9. Knublauch H, Kontokostas D (eds.). (2017). Shapes Constraint Language (SHACL). W3C Recommendation, 20 July 2017, World Wide Web Consortium. https://www.w3.org/TR/shacl/
  10. Vesteghem C, et al. (2024). Assessing the FAIRness of COVID-19 datasets: a meta-research study of pandemic data resources. (meta-research scoring COVID-19 datasets against the four FAIR principles — Findable, Accessible, Interoperable, Reusable; nearly all the datasets were Findable, but only 46.7% were even moderately Interoperable — the "I" in FAIR, the very principle ontologies exist to support.)
  11. Industrial Ontologies Foundry (IOF) / OAGi / NIIMBL. (2024-2025). Biopharmaceutical Manufacturing reference ontologies (developed within the Biopharmaceutical Manufacturing Industry Council, BMIC). Open-source release. https://github.com/iofoundry/ontology

Chapter 15 — The Digital Thread and the Digital Twin​

  1. Grieves M, Vickers J. (2017). Digital Twin: Mitigating Unpredictable, Undesirable Emergent Behavior in Complex Systems. In: Kahlen FJ, Flumerfelt S, Alves A (eds), Transdisciplinary Perspectives on Complex Systems: New Findings and Approaches, Springer, Cham, pp. 85-113. https://doi.org/10.1007/978-3-319-38756-7_4
  2. Kritzinger W, Karner M, Traar G, Henjes J, Sihn W. (2018). Digital Twin in manufacturing: A categorical literature review and classification. IFAC-PapersOnLine 51(11):1016-1022 (16th IFAC Symposium INCOM 2018). https://doi.org/10.1016/j.ifacol.2018.08.474
  3. Tao F, Zhang H, Liu A, Nee AYC. (2019). Digital Twin in Industry: State-of-the-Art. IEEE Transactions on Industrial Informatics 15(4):2405-2415. https://doi.org/10.1109/TII.2018.2873186
  4. Udugama IA, Lopez PC, Gargalo CL, Li X, Bayer C, Gernaey KV. (2021). Digital Twin in biomanufacturing: challenges and opportunities towards its implementation. Systems Microbiology and Biomanufacturing 1(3):257-274. https://doi.org/10.1007/s43393-021-00024-0
  5. Sokolov M, von Stosch M, Narayanan H, Feidl F, Butté A. (2021). Hybrid modeling — a key enabler towards realizing digital twins in biopharma?. Current Opinion in Chemical Engineering 34:100715. https://doi.org/10.1016/j.coche.2021.100715
  6. Konstantinov KB, Cooney CL. (2015). White Paper on Continuous Bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268
  7. International Society of Automation (ISA). (2025). ANSI/ISA-95.00.01-2025 (IEC 62264-1 Mod), Enterprise-Control System Integration — Part 1: Models and Terminology. International Society of Automation; modified adoption of IEC 62264-1 Edition 2. https://www.isa.org/products/ansi-isa-95-00-01-2025-iec-62264-1-mod-enterprise
  8. ICH (International Council for Harmonisation). (2009). ICH Q8(R2) Pharmaceutical Development. ICH Harmonised Tripartite Guideline (Step 4); EMA ref. EMA/CHMP/ICH/167068/2004. https://www.ema.europa.eu/en/ich-q8-r2-pharmaceutical-development-scientific-guideline
  9. FDA (U.S. Food and Drug Administration). (2004). Guidance for Industry — PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. U.S. FDA, CDER/CVM/ORA; final guidance issued September 2004 (Federal Register notice 69 FR 59257, Oct 4, 2004). https://www.fda.gov/media/71012/download
  10. European Medicines Agency (EMA), CHMP/QWP. (2012). Guideline on Real Time Release Testing (formerly Guideline on Parametric Release), Revision 1. European Medicines Agency, EMA/CHMP/QWP/811210/2009 Rev 1 (final 29 Mar 2012; effective 1 Oct 2012). https://www.ema.europa.eu/en/real-time-release-testing-scientific-guideline
  11. Bhowmik S, Anandakrishnan M, Klein L, Arighi C, Gioioso M, Wu C, Brockmeier A, Vijay-Shanker K, Chen C. (2026). Integrating text mining and knowledge graph to enhance biopharmaceutical process optimization. PLOS ONE 21(1):e0339197. https://doi.org/10.1371/journal.pone.0339197

Chapter 16 — From Data to Knowledge: SPC, Multivariate Analysis, and Continued Process Verification​

  1. FDA (U.S. Food and Drug Administration), CDER, CBER, CVM. (2011). Guidance for Industry — Process Validation: General Principles and Practices. U.S. Department of Health and Human Services, Food and Drug Administration; Docket No. FDA-2008-D-0559 (Current Good Manufacturing Practices, Revision 1), January 2011. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices
  2. Nomikos P, MacGregor JF. (1995). Multivariate SPC Charts for Monitoring Batch Processes. Technometrics 37(1):41-59. https://doi.org/10.1080/00401706.1995.10485888
  3. Nomikos P, MacGregor JF. (1994). Monitoring Batch Processes Using Multiway Principal Component Analysis. AIChE Journal 40(8):1361-1375. https://doi.org/10.1002/aic.690400809
  4. Kourti T, MacGregor JF. (1995). Process Analysis, Monitoring and Diagnosis, Using Multivariate Projection Methods. Chemometrics and Intelligent Laboratory Systems 28(1):3-21. https://doi.org/10.1016/0169-7439(95)80036-9
  5. MacGregor JF, Kourti T. (1995). Statistical Process Control of Multivariate Processes. Control Engineering Practice 3(3):403-414. https://doi.org/10.1016/0967-0661(95)00014-L
  6. ICH (International Council for Harmonisation). (2008). ICH Q10 Pharmaceutical Quality System. ICH Harmonised Tripartite Guideline (Step 4, June 2008); EMA ref. EMA/CHMP/ICH/214732/2007. https://www.ema.europa.eu/en/ich-q10-pharmaceutical-quality-system-scientific-guideline
  7. Montgomery DC. (2019). Introduction to Statistical Quality Control, 8th Edition. Wiley, Hoboken NJ; ISBN 978-1-119-39930-8. https://www.wiley.com/en-us/Introduction+to+Statistical+Quality+Control,+8th+Edition-p-9781119399308
  8. Woodall WH. (2000). Controversies and Contradictions in Statistical Process Control (with discussion). Journal of Quality Technology 32(4):341-378. https://doi.org/10.1080/00224065.2000.11980013
  9. Pétillot L, Pewny F, Wolf M, Sanchez C, Thomas F, Sarrazin J, Fritsch K, Offersgaard A, Toth I, Krause F, et al. (2020). Calibration transfer for bioprocess Raman monitoring using Kennard Stone piecewise direct standardization and multivariate algorithms. Engineering in Life Sciences 20(7):289-303. https://doi.org/10.1002/elsc.202000035
  10. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q2-R2_Guideline_2023_1130.pdf
  11. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q14: Analytical Procedure Development. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116.pdf

Chapter 17 — Machine Learning, Soft Sensors, and Hybrid Models​

  1. von Stosch M, Oliveira R, Peres J, Feyo de Azevedo S. (2014). Hybrid semi-parametric modeling in process systems engineering: Past, present and future. Computers & Chemical Engineering 60:86-101. https://doi.org/10.1016/j.compchemeng.2013.08.008
  2. von Stosch M, Davy S, Francois K, Galvanauskas V, Hamelink J-M, Luebbert A, Mayer M, Oliveira R, O'Kennedy R, Rice P, Glassey J. (2014). Hybrid modeling for quality by design and PAT-benefits and challenges of applications in biopharmaceutical industry. Biotechnology Journal 9(6):719-726. https://doi.org/10.1002/biot.201300385
  3. Glassey J, von Stosch M (Eds.). (2018). Hybrid Modeling in Process Industries. CRC Press / Taylor & Francis; ISBN 9781498740869. https://doi.org/10.1201/9781351184373
  4. U.S. Food and Drug Administration (FDA), CDER. (2023). Artificial Intelligence in Drug Manufacturing (Discussion Paper). FDA CDER FRAME Initiative; Docket No. FDA-2023-N-0487. https://www.fda.gov/media/165743/download
  5. Helleckes LM, Hemmerich J, Wiechert W, von Lieres E, Grünberger A. (2023). Machine learning in bioprocess development: from promise to practice. Trends in Biotechnology 41(6):817-835. https://doi.org/10.1016/j.tibtech.2022.10.010
  6. Kadlec P, Gabrys B, Strandt S. (2009). Data-driven Soft Sensors in the process industry. Computers & Chemical Engineering 33(4):795-814. https://doi.org/10.1016/j.compchemeng.2008.12.012
  7. Brunner V, Siegl M, Geier D, Becker T. (2021). Challenges in the Development of Soft Sensors for Bioprocesses: A Critical Review. Frontiers in Bioengineering and Biotechnology 9:722202. https://doi.org/10.3389/fbioe.2021.722202
  8. Narayanan H, Sokolov M, Morbidelli M, Butté A. (2019). A new generation of predictive models: The added value of hybrid models for manufacturing processes of therapeutic proteins. Biotechnology and Bioengineering 116(10):2540-2549. https://doi.org/10.1002/bit.27097
  9. Mowbray M, Savage T, Wu C, Song Z, Cho BA, Del Rio-Chanona EA, Zhang D. (2021). Machine learning for biochemical engineering: A review. Biochemical Engineering Journal 172:108054. https://doi.org/10.1016/j.bej.2021.108054
  10. FDA (U.S. Food and Drug Administration). (2025). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products — Draft Guidance for Industry. FDA, CDER/CBER, January 2025. https://www.fda.gov/media/184830/download
  11. European Commission. (2025). EudraLex Volume 4, EU GMP Annex 22: Artificial Intelligence — Draft for Public Consultation. Published July 2025 — the first GMP annex written specifically for AI/ML in GxP manufacturing. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  12. European Commission / EMA. (2025). EudraLex Volume 4, EU GMP Annex 11: Computerised Systems — Revised Draft for Public Consultation. Published 7 July 2025 (consultation closed October 2025; finalization expected 2026); expands coverage to audit-trail review, cloud/SaaS service providers, data integrity across networked multi-system environments and AI/ML, and formalizes ALCOA+. https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
  13. ISPE (International Society for Pharmaceutical Engineering). (2022). GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems (Second Edition). ISPE, July 2022 (Appendix D11 addresses AI/ML).
  14. ISPE (International Society for Pharmaceutical Engineering). (2025). GAMP Guide: Artificial Intelligence. ISPE, 2025.
  15. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q2-R2_Guideline_2023_1130.pdf
  16. ICH (International Council for Harmonisation). (2023). ICH Harmonised Guideline Q14: Analytical Procedure Development. Step 4, 1 November 2023. https://database.ich.org/sites/default/files/ICH_Q14_Guideline_2023_1116.pdf

Chapter 18 — Real-Time Integration and Pharma 4.0: The Smart, Continuous Factory​

  1. International Council for Harmonisation (ICH). (2023). Q13 Continuous Manufacturing of Drug Substances and Drug Products: Guidance for Industry. U.S. Food and Drug Administration (Docket FDA-2021-D-1047); ICH Harmonised Guideline, Step 4 (endorsed Nov 2022). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q13-continuous-manufacturing-drug-substances-and-drug-products
  2. Konstantinov KB, Cooney CL. (2015). White Paper on Continuous Bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium. Journal of Pharmaceutical Sciences 104(3):813-820. https://doi.org/10.1002/jps.24268
  3. Godawat R, Konstantinov K, Rohani M, Warikoo V. (2015). End-to-end integrated fully continuous production of recombinant monoclonal antibodies. Journal of Biotechnology 213:13-19. https://doi.org/10.1016/j.jbiotec.2015.06.393
  4. International Society for Pharmaceutical Engineering (ISPE). (2023). ISPE Baseline Guide Volume 8: Pharma 4.0 (First Edition). International Society for Pharmaceutical Engineering (ISPE), North Bethesda, MD. https://guidance-docs.ispe.org/doi/book/10.1002/9781946964724
  5. U.S. Food and Drug Administration (FDA), CDER. (2017). Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization: Guidance for Industry. U.S. Food and Drug Administration, Center for Drug Evaluation and Research (Docket FDA-2015-D-4644). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/advancement-emerging-technology-applications-pharmaceutical-innovation-and-modernization-guidance
  6. European Medicines Agency (EMA), CHMP/QWP. (2012). Guideline on Real Time Release Testing (formerly Guideline on Parametric Release), Revision 1. European Medicines Agency, EMA/CHMP/QWP/811210/2009 Rev 1 (final 29 Mar 2012; effective 1 Oct 2012). https://www.ema.europa.eu/en/real-time-release-testing-scientific-guideline
  7. International Society of Automation (ISA) / IEC. (2025). ANSI/ISA-95.00.01-2025 (IEC 62264-1 Mod) Enterprise-Control System Integration - Part 1: Models and Terminology. International Society of Automation (ISA), Research Triangle Park, NC; international equivalent IEC 62264-1. https://www.isa.org/products/ansi-isa-95-00-01-2025-iec-62264-1-mod-enterprise
  8. Chen Y, Yang O, Sampat C, Bhalode P, Ramachandran R, Ierapetritou M. (2020). Digital Twins in Pharmaceutical and Biopharmaceutical Manufacturing: A Literature Review. Processes 8(9):1088. https://doi.org/10.3390/pr8091088
  9. U.S. Food and Drug Administration (FDA), CDER. (2023). Artificial Intelligence in Drug Manufacturing: A Discussion Paper. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. https://www.fda.gov/media/165743/download
  10. Industrial Ontologies Foundry (IOF) / OAGi / NIIMBL. (2024-2025). Biopharmaceutical Manufacturing reference ontologies (developed within the Biopharmaceutical Manufacturing Industry Council, BMIC). Open-source release. https://github.com/iofoundry/ontology
  11. NIIMBL / Open Applications Group (OAGi). (2024). NIIMBL and OAGi Partner to Develop Open-Source Biopharmaceutical Manufacturing Ontologies (the NIST-supported real-time laboratory-data / semantic-interoperability program for continuous and intensified processing). Press release, June 2024. https://www.prnewswire.com/news-releases/niimbl-and-open-applications-group-oagi-partner-to-develop-open-source-biopharmaceutical-manufacturing-ontologies-302172016.html

Image credits & colophon​

Sources and licenses for every image used in this book. Photographs are reproduced under the stated public-domain or Creative Commons (CC) terms, with attribution. Two of the photographs carry a CC BY-SA 4.0 licence, whose "share-alike" condition means anyone who modifies that image must release the modified version under the same licence. Because we use both images unmodified — with full attribution and a link to the licence — that condition attaches only to those images and to adaptations of them, not to this book as a whole: assembling images into a larger collective work does not, by itself, place the share-alike licence on the whole book. Every schematic marked “Original diagram by the authors” was created by the authors with AI assistance and may be reproduced with attribution to the authors. A final legal review is recommended before commercial print publication.

  • “One process, two products”. Original diagram by the authors, created with AI assistance.
  • Filled vials of drug product. Image by CSIRO, CC BY 3.0, via Wikimedia Commons.
  • “The data shadow of a single batch”. Original diagram by the authors, created with AI assistance.
  • Fed-batch sampling. Image by Luis Fernando Flores LAB, licensed under CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/), via Wikimedia Commons; used unmodified.
  • Bench-scale bioreactor. Image by Jonas Schenk, released into the public domain, via Wikimedia Commons.
  • Process chromatography skid. Image by Kitmondo Lab, CC BY 2.0, via Wikimedia Commons.
  • “What batch genealogy looks like in data”. Original diagram by the authors, created with AI assistance.
  • Industrial bioreactor schematic. Image by NIST (U.S. government work, public domain), via Wikimedia Commons.
  • Laboratory centrifuge. Image by Ivangiesen, CC0 (public-domain dedication), via Wikimedia Commons.
  • “How control systems create data”. Original diagram by the authors, created with AI assistance.
  • Laminar-flow cabinet. Image by syed sajidul islam, licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), via Wikimedia Commons; used unmodified.
  • “The plant information-system constellation”. Original diagram by the authors, created with AI assistance.
  • Integrated USP/DSP plant. Image by CC1984USA, licensed under CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/), via Wikimedia Commons; used unmodified.
  • “The ISA-95 / Purdue automation hierarchy”. Original diagram by the authors, created with AI assistance.
  • “Where each connectivity standard lives”. Original diagram by the authors, created with AI assistance.
  • Cleanroom (illustrative; not biopharma-specific). Image by UCL Mathematical and Physical Sciences, CC BY 2.0, via Wikimedia Commons.
  • “How Part 11 and Annex 11 sit atop the predicate rules”. Original diagram by the authors, created with AI assistance.
  • “CSA: risk-proportionate testing”. Original diagram by the authors, created with AI assistance.
  • “A master-data governance lifecycle”. Original diagram by the authors, created with AI assistance.
  • “Pairwise mappings vs one shared model”. Original diagram by the authors, created with AI assistance.
  • “From heterogeneity to FAIR through an ontology”. Original diagram by the authors, created with AI assistance.
  • “Anatomy of a digital twin”. Original diagram by the authors, created with AI assistance.
  • “From hundreds of variables to two charts”. Original diagram by the authors, created with AI assistance.
  • “Mechanistic, data-driven, and hybrid models”. Original diagram by the authors, created with AI assistance.
  • “A Pharma 4.0 smart factory”. Original diagram by the authors, created with AI assistance.